-
Finance
SR MEDICAL (00108.HK): Appoints Shao Jiyou as executive director, annual remuneration HKD 540,000
-
Finance
CSPC PHARMA (01093.HK): Phase II Trial of SYH2069 Injection for Adult Type 2 Diabetes Commences at First Site in China
-
Finance
PATEO (02889.HK): Procurement Centre Vice President Liang Chen Increases H Shareholding by 27,740 Shares and Undertakes a 12-Month Lock-Up
-
Finance
CHINA RUYI (00136.HK): Discloses AI Strategy Progress, Subsidiary Enters into Five-Year Cloud Service Agreement
-
Finance
DIT GROUP (00726.HK): Appoints Chen Aiguo as Executive Director with Annual Remuneration of About HKD 120,000
-
Finance
SUN HING PRINT (01975.HK): Positive Profit Alert, Expects FY2026 Profit of About HKD 10.0 Million to HKD 20.0 Million
-
Finance
HANSOH PHARMA (03692.HK): Class 1 Innovative Drug HS-20197 for Injection Receives Clinical Trial Approval Notice, Intended for Advanced Solid Tumours
-
Finance
SSY GROUP (02005.HK): Ziprasidone Mesylate Approved for Registration as API for Use in Marketed Formulations
-
Finance
PCCW (00008.HK): Joint Announcement with HKT-SS on Completion of Disposal of Interest in a Subsidiary for Total Consideration of USD 209,452,500
-
Finance
PSBC (01658.HK): Sun Maozhu's Qualification Approved for Appointment as Independent Non-Executive Director, Zhong Ruiming Retires by Rotation
-
-
Scan QR Code
Download App
